SightGlass Earns CE Mark for Eyeglasses That Slow Myopia Progression in Children

By


PALO ALTO, Calif.—SightGlass Vision, a life sciences company focused on ending nearsightedness (myopia), announced on Wednesday that it has achieved Conformite Europeene (CE) Mark declaration on its first product, a novel eyeglass designed to slow the progression of myopia in children. The CE Mark confirms that SightGlass Vision’s Diffusion Optics Technology (DOT) spectacle lens products meet European Union (EU) regulatory standards, and allows the company to commercialize its suite of DOT products across the EU, U.K., and other European Economic Area countries.

The CE Mark declaration allowing European Marketing Authorization includes products containing anti-reflective and photochromic technologies, making the company’s DOT lenses the first product that has shown success in a multi-center, randomized, controlled clinical trial to include these options for myopia management.

Thomas W. Chalberg, PhD, founder and CEO., said, “Our novel spectacle lenses designed to slow myopia progression in children have been hailed as a revolutionary innovation in the field of myopia management. The CE Mark allowing European Marketing Authorization for our suite of DOT products is an important leap forward for our company, as we advance our mission to end myopia. We look forward to bringing to market a powerful and unique mechanism of action that we are confident will benefit children in the EU and other CE Mark geographies who live with myopia and are at risk from its vision-threatening complications.”

The CE Mark is a certification mark in Europe that signals conformity to patient and user safety and device performance standards in the region. It is considered an essential regulatory requirement for companies intending to sell medical products in the European Economic Area.

SightGlass Vision also received ISO 13485:2016 certification of its manufacturing process, facility, and quality management system in 2019. In addition, SightGlass Vision’s quality systems meet the new EU rules for medical device manufacturers, known as Medical Devices Regulation, which is scheduled to take effect on May 26, 2021.